Inhibikase Therapeutics, Inc.
IKT
$1.84
$0.084.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -41.50M | -36.55M | -27.52M | -19.57M | -18.38M |
| Total Depreciation and Amortization | 50.10K | 32.50K | 26.40K | 26.40K | 26.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.14M | 16.32M | 8.14M | 368.60K | 367.70K |
| Change in Net Operating Assets | 1.41M | 810.30K | 205.00K | 1.93M | 1.52M |
| Cash from Operations | -19.90M | -19.38M | -19.15M | -17.24M | -16.47M |
| Capital Expenditure | -13.40K | -13.40K | -- | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -5.32M | -12.62M | -37.00M | -358.10K | 14.18M |
| Cash from Investing | -5.34M | -12.64M | -37.00M | -358.10K | 14.18M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 99.90M | 103.08M | 103.48M | 3.79M | 3.61M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 30.60K | 0.00 | -138.60K | -138.60K |
| Cash from Financing | 99.90M | 103.11M | 103.48M | 3.66M | 3.47M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 74.66M | 71.09M | 47.33M | -13.95M | 1.18M |